Table of Content

1 Middle East Liquid Biopsy Market
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.1.2 Key Questions Answered in the Report
1.2 Research Methodology
1.2.1 Primary Data Sources
1.2.2 Source: BIS Research Analysis Secondary Data Sources
1.3 Market Estimation Model

2 Market Overview
2.1 Market Definition
2.2 Emerging Applications of Liquid Biopsy
2.3 Market Footprint and Growth Potential, $Million, 2021-2032
2.4 COVID-19 Impact on the Middle East Liquid Biopsy Market

3 Industry Insights
3.1 Patent Analysis
3.1.1 Key Players Patent Portfolio
3.1.2 Patent Filing Analysis
3.1.3 Key Players Patent Expiration Analysis
3.2 Legal Requirements and Regulations

4 Competitive Landscape
4.1 Key Strategies and Developments
4.1.1 Agreement and Partnership
4.1.2 Regulatory Accreditations
4.1.3 Product and Service Launches
4.1.4 Mergers and Acquisitions
4.1.5 Approvals

5 Market Dynamics
5.1 Market Dynamics
5.1.1 Impact Analysis
5.2 Market Drivers
5.2.1 Liquid Biopsy Demand Inclined by Rising Prevalence of Cancer
5.2.2 Rise in Patient Preference for Non-Invasive Cancer Diagnosis
5.2.3 Potential of Liquid Biopsy
5.3 Market Restraints
5.3.1 False Negatives and Positives
5.3.2 Existing Diagnostic Confidence in Conventional Tissue-Based Diagnosis Practices
5.4 Market Opportunities
5.4.1 Potential Cost Savings
5.4.2 Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy

6 Middle East Liquid Biopsy Market, by Product, $Million, 2022 - 2032
6.1 Overview
6.2 Tests/Services
6.3 Kits and Consumables
6.4 Instruments

7 Middle East Liquid Biopsy Market, by Technology, $Million, 2021 - 2032
7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
7.3 Next-Generation Sequencing (NGS)
7.4 Fluorescence In-Situ Hybridization (FISH)
7.5 Other Technologies

8 Middle East Liquid Biopsy Market, by Workflow, $Million, 2021 - 2032
8.1 Overview
8.2 Sample Preparation
8.3 Library Preparation
8.4 Sequencing
8.5 Data Analysis

9 Middle East Liquid Biopsy Market, by Usage, $Million, 2021 - 2032
9.1 Overview
9.2 Research Use Only (RUO)
9.3 Clinical

10 Middle East Liquid Biopsy Market, by Sample, $Million, 2021 - 2032
10.1 Overview
10.2 Blood
10.3 Urine
10.4 Saliva
10.5 Cerebrospinal Fluid

11 Middle East Liquid Biopsy Market, by Circulating Biomarker, $Million, 2021 - 2032
11.1 Overview
11.2 Circulating Tumor Cells (CTCs)
11.3 Cell-Free DNA (cfDNA)
11.4 Circulating Cell-Free RNA
11.5 Exosomes and Extracellular Vesicles
11.6 Other Circulating Biomarkers

12 Middle East Liquid Biopsy Market, by Indication, $Million, 2021 - 2032
12.1 Overview
12.2 Lung Cancer
12.3 Breast Cancer
12.4 Prostate Cancer
12.5 Colorectal Cancer
12.6 Melanoma
12.7 Other Cancers
12.8 Non-Oncology Disorder

13 Middle East Liquid Biopsy Market, by Clinical Application, $Million, 2021 - 2032
13.1 Overview
13.2 Treatment Monitoring
13.3 Prognosis and Recurrence Monitoring
13.4 Treatment Selection
13.5 Diagnosis and Screening

14 Middle East Liquid Biopsy Market, by Country, $Million, 2021-2032
14.1 Overview
14.1.1 K.S.A.
14.1.2 Israel
14.1.3 U.A.E.
14.1.4 Egypt
14.1.5 Iran
14.1.6 Qatar
14.1.7 Rest-of-the-Middle East

15 Market - Competitive Benchmarking & Company Profiles
15.1 Overview
15.2 Bio-Rad Laboratories, Inc.
15.2.1 Company Overview
15.2.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Liquid Biopsy Market
15.2.3 Key Competitors of the Company
15.2.4 Key Customers of the Company
15.2.5 Financials
15.2.6 Key Insights about Financial Health of the Company
15.2.7 SWOT Analysis
15.3 Bioscience Institute S.p.A.
15.3.1 Company Overview
15.3.2 Role of Bioscience Institute S.p.A. in the Middle East Liquid Biopsy Market
15.3.3 Key Competitors of the Company
15.3.4 Key Customers of the Company
15.3.5 SWOT Analysis
15.4 Eurofins Scientific
15.4.1 Company Overview
15.4.2 Role of Eurofins Scientific in the Middle East Liquid Biopsy Market
15.4.3 Key Competitors of the Company
15.4.4 Key Customers of the Company
15.4.5 Business Strategies
15.4.6 Financials
15.4.7 SWOT Analysis
15.5 F. Hoffmann-La Roche Ltd
15.5.1 Company Overview
15.5.2 Role of F. Hoffmann-La Roche Ltd in the Middle East Liquid Biopsy Market
15.5.3 Key Competitors of the Company
15.5.4 Key Customers of the Company
15.5.5 Business Strategies
15.5.6 Financials
15.5.7 Key Insights about Financial Health of the Company
15.5.8 SWOT Analysis
15.6 Guardant Health
15.6.1 Company Overview
15.6.2 Role of Guardant Health in the Middle East Liquid Biopsy Market
15.6.3 Key Competitors of the Company
15.6.4 Key Customers of the Company
15.6.5 Business Strategies
15.6.6 Financials
15.6.7 Key Insights about Financial Health of the Company
15.6.8 SWOT Analysis
15.7 Illumina, Inc.
15.7.1 Company Overview
15.7.2 Role of Illumina, Inc. in the Middle East Liquid Biopsy Market
15.7.3 Key Competitors of the Company
15.7.4 Key Customers of the Company
15.7.5 Financials
15.7.6 Key Insights about Financial Health of the Company
15.7.7 SWOT Analysis
15.8 Natera, Inc.
15.8.1 Company Overview
15.8.2 Role of Natera, Inc. Limited in the Middle East Liquid Biopsy Market
15.8.3 Key Competitors of the Company
15.8.4 Key Customers of the Company
15.8.5 Financials
15.8.6 Key Insights about Financial Health of the Company
15.8.7 SWOT Analysis
15.9 NeoGenomics Laboratories, Inc.
15.9.1 Company Overview
15.9.2 Role of NeoGenomics Laboratories, Inc. in the Middle East Liquid Biopsy Market
15.9.3 Key Competitors of the Company
15.9.4 Key Customers of the Company
15.9.5 Corporate Strategies
15.9.6 Financials
15.9.7 Key Insights about Financial Health of the Company
15.9.8 SWOT Analysis
15.1 PerkinElmer Inc.
15.10.1 Company Overview
15.10.2 Role of PerkinElmer Inc. in the Middle East Liquid Biopsy Market
15.10.3 Key Competitors of the Company
15.10.4 Key Customers of the Company
15.10.5 Financials
15.10.6 Key Insights about Financial Health of the Company
15.10.7 SWOT Analysis
15.11 QIAGEN N.V.
15.11.1 Company Overview
15.11.2 Role of QIAGEN N.V. in the Middle East Liquid Biopsy Market
15.11.3 Key Competitors of the Company
15.11.4 Key Customers of the Company
15.11.5 Financials
15.11.6 Key Insights about Financial Health of the Company
15.11.7 SWOT Analysis
15.12 Sysmex Corporation
15.12.1 Company Overview
15.12.2 Role of Sysmex Corporation in the Middle East Liquid Biopsy Testing Market
15.12.3 Key Competitors of the Company
15.12.4 Key Customers of the Company
15.12.5 Business Strategies
15.12.6 Financials
15.12.7 Key Insights about Financial Health of the Company
15.12.8 SWOT Analysis
15.13 Thermo Fisher Scientific Inc.
15.13.1 Company Overview
15.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East Liquid Biopsy Market
15.13.3 Key Competitors of the Company
15.13.4 Key Customers of the Company
15.13.5 Financials
15.13.6 Key Insights about Financial Health of the Company
15.13.7 SWOT Analysis
List of Figures
Figure 1: Middle East Cancer Burden, 2020
Figure 2: Middle East Liquid Biopsy Market Segmentation
Figure 3: Middle East Liquid Biopsy Market: Research Methodology
Figure 4: Primary Research Methodology
Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
Figure 6: Top-Down Approach (Segment-Wise Analysis)
Figure 7: Middle East Liquid Biopsy Market, $Million, 2021-2032
Figure 8: Share of Patents Filed in the Middle East Liquid Biopsy Market, FY2014-FY2018
Figure 9: Liquid Biopsy Patent Analysis, FY2014-FY2018
Figure 10: : Patent Expiration Analysis
Figure 11: Role of FDA in Advancing Liquid Biopsy
Figure 12: Share of Key Developments and Strategies, January 2017-January 2019
Figure 13: Share (by Company), January 2017-January 2019
Figure 14: Share of Regulatory Accreditations (by Company), January 2017-January 2019
Figure 15: Share of Product and Service Launches (by Company), January 2017-January 2019
Figure 16: Share of Mergers and Acquisitions (by Company), January 2017-January 2019
Figure 17: Approvals (by Company), January 2017-January 2019
Figure 18: Middle East Liquid Biopsy Market Dynamics
Figure 19: Middle East Cancer Burden, 2020
Figure 20: Middle East Liquid Biopsy Market Segmentation (by Product)
Figure 21: Share of Middle East Liquid Biopsy Market (by Product), $Million, 2021 and 2032
Figure 22: Middle East Liquid Biopsy Market (Tests/Services), $Million, 2021-2032
Figure 23: Middle East Liquid Biopsy Market (Kits and Consumables), $Million, 2021-2032
Figure 24: Middle East Liquid Biopsy Market (Instruments), $Million, 2021-2032
Figure 25: Middle East Liquid Biopsy Market (by Technology)
Figure 26: Middle East Liquid Biopsy Market (by Technology), $Million, 2021 and 2032
Figure 27: Middle East Liquid Biopsy Market (Polymerase Chain Reaction (PCR)), $Million, 2021-2032
Figure 28: Middle East Liquid Biopsy Market (Next-Generation Sequencing (NGS)), $Million, 2021-2032
Figure 29: Middle East Liquid Biopsy Market (Fluorescence In-Situ Hybridization (FISH)), $Million, 2021-2032
Figure 30: Middle East Liquid Biopsy Market (Other Technologies), $Million, 2021-2032
Figure 31: Middle East Liquid Biopsy Market (by Workflow)
Figure 32: Middle East Liquid Biopsy Market (by Workflow), $Million, 2021 and 2032
Figure 33: Middle East Liquid Biopsy Market (Sample Preparation), $Million, 2021-2032
Figure 34: Middle East Liquid Biopsy Market (Library Preparation), $Million, 2021-2032
Figure 35: Middle East Liquid Biopsy Market (Sequencing), $Million, 2021-2032
Figure 36: Middle East Liquid Biopsy Market (Data Analysis), $Million, 2021-2032
Figure 37: Middle East Liquid Biopsy Market (by Usage)
Figure 38: Middle East Liquid Biopsy Market (by Usage), $Million, 2021 and 2032
Figure 39: Middle East Liquid Biopsy Market (Research Use Only (RUO)), $Million, 2021-2032
Figure 40: Middle East Liquid Biopsy Market (Clinical), $Million, 2021-2032
Figure 41: Middle East Liquid Biopsy Market (by Sample)
Figure 42: Middle East Liquid Biopsy Market (by Sample), $Million, 2021 and 2032
Figure 43: Middle East Liquid Biopsy Market (Blood), $Million, 2021-2032
Figure 44: Middle East Liquid Biopsy Market (Urine), $Million, 2021-2032
Figure 45: Middle East Liquid Biopsy Market (Saliva), $Million, 2021-2032
Figure 46: Middle East Liquid Biopsy Market (Cerebrospinal Fluid), $Million, 2021-2032
Figure 47: Middle East Liquid Biopsy Market (by Circulating Biomarker)
Figure 48: Middle East Liquid Biopsy Market (by Circulating Biomarker), $Million, 2021 and 2032
Figure 49: Middle East Liquid Biopsy Market (Circulating Tumor Cells (CTCs)), $Million, 2021-2032
Figure 50: Middle East Liquid Biopsy Market (Cell-Free DNA (cfDNA)), $Million, 2021-2032
Figure 51: Middle East Liquid Biopsy Market (Circulating Cell-Free RNA), $Million, 2021-2032
Figure 52: Middle East Liquid Biopsy Market (Exosomes and Extracellular Vesicles), $Million, 2021-2032
Figure 53: Middle East Liquid Biopsy Market (Other Circulating Biomarkers), $Million, 2021-2032
Figure 54: Middle East Liquid Biopsy Market (by Indication)
Figure 55: Middle East Liquid Biopsy Market (by Indication), $Million, 2021 and 2032
Figure 56: Middle East Liquid Biopsy Market (Lung Cancer), $Million, 2021-2032
Figure 57: Middle East Liquid Biopsy Market (Breast Cancer), $Million, 2021-2032
Figure 58: Middle East Liquid Biopsy Market (Prostate Cancer), $Million, 2021-2032
Figure 59: Middle East Liquid Biopsy Market (Colorectal Cancer), $Million, 2021-2032
Figure 60: Middle East Liquid Biopsy Market (Melanoma), $Million, 2021-2032
Figure 61: Middle East Liquid Biopsy Market (Other Cancers), $Million, 2021-2032
Figure 62: Middle East Liquid Biopsy Market (Non-Oncology Disorder), $Million, 2021-2032
Figure 63: Middle East Liquid Biopsy Market (by Clinical Application)
Figure 64: Middle East Liquid Biopsy Market (by Clinical Application), $Million, 2021 and 2032
Figure 65: Middle East Liquid Biopsy Market (Treatment Monitoring), $Million, 2021-2032
Figure 66: Middle East Liquid Biopsy Market (Prognosis and Recurrence Monitoring), $Million, 2021-2032
Figure 67: Middle East Liquid Biopsy Market (Treatment Selection), $Million, 2021-2032
Figure 68: Middle East Liquid Biopsy Market (Diagnosis and Screening), $Million, 2021-2032
Figure 69: Middle East Liquid Biopsy Market (by Country), $Million, 2021-2032
Figure 70: Middle East Liquid Biopsy Market (by Country), $Million, 2021 and 2032
Figure 71: K.S.A. Liquid Biopsy Market, $Million, 2021-2032
Figure 72: Israel Liquid Biopsy Market, $Million, 2021-2032
Figure 73: U.A.E. Liquid Biopsy Market, $Million, 2021-2032
Figure 74: Egypt Liquid Biopsy Market, $Million, 2021-2032
Figure 75: Iran East Liquid Biopsy Market, $Million, 2021-2032
Figure 76: Qatar Middle East Liquid Biopsy Market, $Million, 2021-2032
Figure 77: Rest-of-the-Middle East Liquid Biopsy Market, $Million, 2021-2032
Figure 78: Total Number of Companies Profiled
Figure 79: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 80: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 81: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 82: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 83: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 84: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 85: Bioscience Institute S.p.A.: Overall Product Portfolio
Figure 86: Bioscience Institute S.p.A.: SWOT Analysis
Figure 87: Eurofins Scientific: Overall Product Portfolio
Figure 88: Eurofins Scientific: Overall Financials, $Million, 2019-2021
Figure 89: Eurofins Scientific: Revenue (by Region), $Million, 2019-2021
Figure 90: Eurofins Scientific: SWOT Analysis
Figure 91: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 92: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 93: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 94: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 95: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 96: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 97: Guardant Health: Overall Product Portfolio
Figure 98: Guardant Health: Overall Financials, $Million, 2019-2021
Figure 99: Guardant Health: Revenue (by Segment), $Million, 2019-2021
Figure 100: Guardant Health: Revenue (by Region), $Million, 2019-2021
Figure 101: Guardant Health: R&D Expenditure, $Million, 2019-2021
Figure 102: Guardant Health.: SWOT Analysis
Figure 103: Illumina, Inc.: Overall Product Portfolio
Figure 104: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 105: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 106: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 107: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 108: Illumina, Inc.: SWOT Analysis
Figure 109: Natera, Inc.: Overall Product Portfolio
Figure 110: Natera, Inc.: Overall Financials, $Million, 2019-2021
Figure 111: Natera, Inc.: Revenue (by Segment), $Million 2019-2021
Figure 112: Natera, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 113: Natera, Inc.: SWOT Analysis
Figure 114: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
Figure 115: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 116: NeoGenomics Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 117: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 118: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 119: PerkinElmer Inc.: Overall Product Portfolio
Figure 120: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
Figure 121: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 122: PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 123: PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 124: PerkinElmer, Inc.: SWOT Analysis
Figure 125: QIAGEN N.V.: Overall Product Portfolio
Figure 126: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 127: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 128: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 129: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 130: QIAGEN N.V. N.V.: SWOT Analysis
Figure 131: Sysmex Corporation: Overall Product Portfolio
Figure 132: Sysmex Corporation: Overall Financials, $Million, 2018-2020
Figure 133: Sysmex Corporation: Revenue (by Region), $Million, 2018-2020
Figure 134: Sysmex Corporation: R&D Expenditure, $Million, 2018-2020
Figure 135: Sysmex Corporation: SWOT Analysis
Figure 136: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 137: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 138: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 139: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 140: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 141: Thermo Fisher Scientific Inc.: SWOT Analysis
List of Tables
Table 1: Middle East Liquid Biopsy Market: Key Players Patent Portfolio
Table 2: Key Players of Liquid Biopsy (Cost Savings)
Table 3: Companies Providing Tests/Services
Table 4: Companies Providing Kits and Consumables
Table 5: Companies Providing Instruments